蓝鲸新闻8月14日讯，近日，湖南证监局发布行政监管措施决定书，剑指湖南南新制药股份有限公司及相关责任人。
决定书显示，湖南南新制药股份有限公司存在以下情形：2021年未及时对退货事项进行会计处理，导致虚增2021年营业收入525.63万元，虚增2021年利润总额157.32万元，虚减2022年利润总额157.32万元；2024年未及时对应收账款折价事项进行会计处理，导致虚增2024年营业收入1,156.33万元。
上述行为违反了《上市公司信息披露管理办法》的相关规定。公司时任董事长杨文逊、时任董事长胡新保、时任总经理张世喜、时任财务总监李亮对上述事项负有主要责任。
针对上述违法行为，湖南证监局对湖南南新制药股份有限公司、杨文逊、胡新保、张世喜和李亮采取出具警示函的行政监管措施，同时记入证券期货市场诚信档案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.